Solid Biosciences Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Solid Biosciences Inc. (SLDB) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $4.78 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-08-06
- Solid Biosciences Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2026-03-31 was $4.78M, a 44.88% decline year-over-year.
- Solid Biosciences Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-03-31 was $8.66M, a 96.62% increase year-over-year.
- Solid Biosciences Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2024-03-31 was $4.41M.
- Solid Biosciences Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2023-12-31 was $11.00K.
- Solid Biosciences Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2025 was $8.66M, a 96.62% increase from fiscal 2024.
- Solid Biosciences Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2024 was $4.41M, a 5698.68% increase from fiscal 2023.
- Solid Biosciences Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2023 was $76.00K, a 96.90% decline from fiscal 2022.
- Solid Biosciences Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2022 was $2.45M, a 72.40% decline from fiscal 2021.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 9 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $4.78M 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $8.66M 10-K · filed 2026-03-19 | ||||
| 2025-03-31 | $8.66M 10-Q · filed 2026-08-06 | ||||
| 2024-12-31 | $4.41M 10-K · filed 2026-03-19 | ||||
| 2024-03-31 | $4.41M 10-Q · filed 2025-11-03 | $4.42M derived: sum of 2 quarters · filed 2025-11-03 | $4.42M derived: sum of 3 quarters · filed 2025-11-03 | $4.48M derived: sum of 4 quarters · filed 2025-11-03 | |
| 2023-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $11.00K derived: sum of 2 quarters · filed 2025-03-06 | $76.00K derived: sum of 3 quarters · filed 2025-03-06 | $76.00K 10-K · filed 2025-03-06 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $65.00K derived: sum of 2 quarters · filed 2023-11-08 | $65.00K 10-Q · filed 2023-11-08 | ||
| 2023-06-30 | $65.00K 10-Q · filed 2023-08-14 | $65.00K 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $2.45M 10-K · filed 2024-03-13 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $8.87M 10-K · filed 2024-03-13 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $8.87M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $8.87M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $8.87M 10-Q · filed 2022-04-27 | ||||
| 2020-12-31 | $3.79M 10-K · filed 2023-03-23 | ||||
| 2019-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $2.10M derived: sum of 2 quarters · filed 2022-03-14 | $2.10M 10-K · filed 2022-03-14 | ||
| 2019-09-30 | $2.08M 10-Q · filed 2020-11-05 | $2.08M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $4.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $4.28M derived: sum of 2 quarters · filed 2022-03-14 | $4.28M derived: sum of 3 quarters · filed 2022-03-14 | $8.87M 10-K · filed 2022-03-14 | $4.59M 10-K · filed 2019-03-13 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $4.59M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $4.59M 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | $4.59M 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |